File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of steroid-induced osteoporosis

TitleManagement of steroid-induced osteoporosis
Authors
Issue Date2000
PublisherChinese Medical Association. The Journal's web site is located at http://www.cmj.org/
Citation
Chinese Medical Journal, 2000, v. 113 n. 8, p. 681-685 How to Cite?
AbstractPurpose: To review the pathogenesis, clinical presentation, diagnostic assessment and treatment regimens of steroid-induced bone loss. Data sources: An English-language literature search (MEDLINE 1966- 1999) and bibliographic reviews of textbooks and review articles. Study selection: Cross-sectional and prospective studies with BMD measurements or fracture rate. Results: The greatest rate of bone loss occur during the first 6 to 12 months of steroid therapy, affecting trabecular more than cortical bone. High steroid dosage for a prolonged period, prevalent fracture, hypogonadism, older age, low calcium intake and family history of osteoporosis are risk factors for steroid-induced bone loss. Based on bone density results, patients with osteoporosis or osteopenia with a T-score below - 1.5 should receive antiresorptive treatment during steroid therapy. Among the various antiresorptive agents, bisphosphonates have the strongest evidence of preventing steroid-induced bone loss. Conclusion: The most important step in the management of steroid-induced osteoporosis is the proper assessment of the individual patient's risk of bone loss, and the selection of appropriate anti-resorptive agent for each patient.
Persistent Identifierhttp://hdl.handle.net/10722/162391
ISSN
2015 Impact Factor: 0.957
2015 SCImago Journal Rankings: 0.428
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLambrinoudaki, Ien_US
dc.contributor.authorKung, AWCen_US
dc.date.accessioned2012-09-05T05:19:33Z-
dc.date.available2012-09-05T05:19:33Z-
dc.date.issued2000en_US
dc.identifier.citationChinese Medical Journal, 2000, v. 113 n. 8, p. 681-685en_US
dc.identifier.issn0366-6999en_US
dc.identifier.urihttp://hdl.handle.net/10722/162391-
dc.description.abstractPurpose: To review the pathogenesis, clinical presentation, diagnostic assessment and treatment regimens of steroid-induced bone loss. Data sources: An English-language literature search (MEDLINE 1966- 1999) and bibliographic reviews of textbooks and review articles. Study selection: Cross-sectional and prospective studies with BMD measurements or fracture rate. Results: The greatest rate of bone loss occur during the first 6 to 12 months of steroid therapy, affecting trabecular more than cortical bone. High steroid dosage for a prolonged period, prevalent fracture, hypogonadism, older age, low calcium intake and family history of osteoporosis are risk factors for steroid-induced bone loss. Based on bone density results, patients with osteoporosis or osteopenia with a T-score below - 1.5 should receive antiresorptive treatment during steroid therapy. Among the various antiresorptive agents, bisphosphonates have the strongest evidence of preventing steroid-induced bone loss. Conclusion: The most important step in the management of steroid-induced osteoporosis is the proper assessment of the individual patient's risk of bone loss, and the selection of appropriate anti-resorptive agent for each patient.en_US
dc.languageengen_US
dc.publisherChinese Medical Association. The Journal's web site is located at http://www.cmj.org/en_US
dc.relation.ispartofChinese Medical Journalen_US
dc.subject.meshAlgorithmsen_US
dc.subject.meshBone Densityen_US
dc.subject.meshBone And Bones - Drug Effectsen_US
dc.subject.meshCalcium - Administration & Dosageen_US
dc.subject.meshCross-Sectional Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshOsteoporosis - Chemically Induced - Prevention & Controlen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshSteroids - Adverse Effectsen_US
dc.subject.meshVitamin D - Administration & Dosageen_US
dc.titleManagement of steroid-induced osteoporosisen_US
dc.typeArticleen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid11776048-
dc.identifier.scopuseid_2-s2.0-0033867702en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033867702&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume113en_US
dc.identifier.issue8en_US
dc.identifier.spage681en_US
dc.identifier.epage685en_US
dc.identifier.isiWOS:000088781300003-
dc.publisher.placeChinaen_US
dc.identifier.scopusauthoridLambrinoudaki, I=6601969370en_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats